TP53 and breast carcinoma: ANVs are also proposed for the targeted delivery of ZMC-1 to reactivate p53, offering a potential therapeutic approach for BRCA1-related breast cancers with p53 mutations and highlighting the versatility of nanoparticle-based strategies in addressing mutp53-driven cancers [119].